Sarami I, Duffield AS, Sundaram S, Lin DI, Salib C, Hussein S, El Jamal S, Ghesani N, Cangut B, Petersen BE. An aggressive hematolymphoid neoplasm with homozygous <i>SMARCB1</i&gt; loss shows response to EZH2 inhibition. Haematologica 2025;110(11):2849-2854; https://doi.org/10.3324/haematol.2024.285776.